Astellas furthers oncology ambitions with $765 million Medivation deal
This article was originally published in Scrip
Astellas has acquired global rights to Medivation's investigational prostate cancer drug MDV3100, in an alliance worth up to $765 million in up-front and milestone payments to the US firm.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.